Get the Weekly Intelligence Brief — top committee picks every Sunday.
NVST · NYSE · STOCK

Envista Holdings (NVST) Stock Analysis

Healthcare Updated October 10, 2026
$22.99
52W $18.77 – $30.42
65/100
$3.74B
39.0
0.89
AI Committee Verdict
Buy
65/100
Conviction: High · 80% agreement · 5 analysts
+11.4%
-2.0%
5.66:1
High

Is NVST Bullish or Bearish?

Bullish. Innellis AI committee rates Envista Holdings (NVST) Buy with a composite score of 65/100 , based on 5 analysts with 80% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +9.88 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -10.12 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Growth Analyst sees a compelling case — eps growing 83.6% yoy. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Price-to-book of 1.1x is a discount to asset value — Value
  • EPS growing 83.6% YoY — Growth
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • P/E of 38.7 is moderate-to-rich — Value
  • ROE of only 3.1% -- cheap may mean cheap for a reason — Value
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
65/100
Agreement
80%
Analysts
5
Conviction
High
Sector Rank
Top 4%
of 192 Healthcare peers
Value Analyst neutral
55 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ Price-to-book of 1.1x is a discount to asset value
− P/E of 38.7 is moderate-to-rich
Growth Analyst bullish
79 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 83.6% YoY
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ MACD histogram positive -- bullish momentum
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
66 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.25 across 8 articles, 14d)
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 64.4 to 65.1.

Analyst-level changes:
  • News Analyst: score 70->66 (-4); +1 bullish signal(s).
  • Technical Analyst: stance neutral->bullish; score 54->61 (+8).
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
34.9
Neutral
MACD Histogram
0.023
Bullish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Mixed
Support
$22.52
Resistance
$25.62
Bollinger %B
0.25
Inside Bands
Price vs Moving Averages
EMA 9
$23.24 Below
EMA 21
$23.97 Below
EMA 50
$25.08 Below
EMA 200
$24.93 Below

Fundamental Analysis

Valuation
68
Growth
95
Profitability
30
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio 39.0×
P/B Ratio 1.21×
PEG Ratio 0.43
Dividend Yield 0.00%
52W High $30.42
52W Low $18.77
Quality & Growth
ROE 151.3%
ROA 82.8%
Gross Margin 5549.8%
Operating Margin 992.1%
Revenue Growth YoY —
Debt / Equity 0.52
AI Fundamental Assessment
P/E ratio of 39.0 (rich relative to a 15-40x range); Price-to-book of 1.2x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 1.5%; Return on assets of 0.8%; Net margin of 3.3%; Gross margin of 55.5%; Current ratio of 2.43 (healthy short-term liquidity); Debt-to-equity of 0.52; Free cash flow per share is positive (1.43); Most recent quarter beat estimates by 19.9%; 5 consecutive earnings beats; EPS growth accelerating (-5.3% -> +13.9% QoQ); Average YoY EPS growth of 57.7%; Analyst estimates rising over recent quarters
Get the Full NVST Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime